Compare · BSX vs ICU
BSX vs ICU
Side-by-side comparison of Boston Scientific Corporation (BSX) and SeaStar Medical Holding Corporation (ICU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and ICU operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.36B, about 3302.6x ICU ($19.2M).
- Over the past year, BSX is down 58.8% and ICU is down 12.5% - ICU leads by 46.3 points.
- ICU has been more active in the news (11 items in the past 4 weeks vs 2 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 0 for ICU).
- Company
- Boston Scientific Corporation
- SeaStar Medical Holding Corporation
- Price
- $42.63-4.55%
- $4.87+1.46%
- Market cap
- $63.36B
- $19.2M
- 1M return
- -9.63%
- +78.39%
- 1Y return
- -58.78%
- -12.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 11
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest ICU
- SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
- Chief Executive Officer Schlorff Eric was granted 10,288 shares, increasing direct ownership by 26% to 50,140 units (SEC Form 4)
- Chief Medical Officer Chung Kevin was granted 7,202 shares, increasing direct ownership by 35% to 28,021 units (SEC Form 4)
- Director Vincent Bernadette N was granted 4,000 shares, increasing direct ownership by 95% to 8,200 units (SEC Form 4)
- Director Neuman John was granted 4,000 shares, increasing direct ownership by 33% to 16,200 units (SEC Form 4)
- Director Van Heel Kenneth was granted 4,000 shares, increasing direct ownership by 50% to 11,940 units (SEC Form 4)
- Director Baird Jennifer A was granted 4,000 shares, increasing direct ownership by 60% to 10,620 units (SEC Form 4)
- SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update
- SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury